Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Clinuvel Pharmaceuticals Provides Corporate Update

31 Jul 2020  |  09:24:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: CLINUVEL Corporate Update

Clinuvel Pharmaceuticals provided corporate update. has It delivered on a longstanding strategic objective to develop and commercialise a novel pharmaceutical product, SCENESSE (afamelanotide 16mg), which has been approved and launched for adult patients with the rare genetic disorder erythropoietic protoporphyria (EPP) in Europe and the USA. It has expanded access to SCENESSE throughout 2020, despite the COVID-19 pandemic.

Please click here for full details

See more ASX300 News Announcements